These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 25392292)

  • 21. Synthetic cannabinoid and cathinone use among US soldiers.
    Berry-Cabán CS; Kleinschmidt PE; Rao DS; Jenkins J
    US Army Med Dep J; 2012; ():19-24. PubMed ID: 23007932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
    Gillet C; Polard E; Mauduit N; Allain H
    Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct analysis in real time mass spectrometry with collision-induced dissociation for structural analysis of synthetic cannabinoids.
    Musah RA; Domin MA; Cody RB; Lesiak AD; Dane AJ; Shepard JR
    Rapid Commun Mass Spectrom; 2012 Oct; 26(19):2335-42. PubMed ID: 22956326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and structural elucidation of four cannabimimetic compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in seized products.
    Denooz R; Vanheugen JC; Frederich M; de Tullio P; Charlier C
    J Anal Toxicol; 2013 Mar; 37(2):56-63. PubMed ID: 23339188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
    D'Souza DC; Abi-Saab WM; Madonick S; Forselius-Bielen K; Doersch A; Braley G; Gueorguieva R; Cooper TB; Krystal JH
    Biol Psychiatry; 2005 Mar; 57(6):594-608. PubMed ID: 15780846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An accidental fatal intoxication with methoxetamine.
    Wikström M; Thelander G; Dahlgren M; Kronstrand R
    J Anal Toxicol; 2013; 37(1):43-6. PubMed ID: 23111916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Headache after substance abuse: a diagnostic dilemma.
    Kamat AS; Aliashkevich AF; Denton JR; Fitzjohn TP
    J Clin Neurosci; 2012 Mar; 19(3):464-6. PubMed ID: 22245279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The synthetic cannabinoid 5F-MDMB-PICA: A case series.
    Kleis J; Germerott T; Halter S; Héroux V; Roehrich J; Schwarz CS; Hess C
    Forensic Sci Int; 2020 Sep; 314():110410. PubMed ID: 32683270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: A case series.
    Barceló B; Pichini S; López-Corominas V; Gomila I; Yates C; Busardò FP; Pellegrini M
    Forensic Sci Int; 2017 Apr; 273():e10-e14. PubMed ID: 28190538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designer drugs 2015: assessment and management.
    Weaver MF; Hopper JA; Gunderson EW
    Addict Sci Clin Pract; 2015 Mar; 10(1):8. PubMed ID: 25928069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bonzai, lead and bath salt-poisoning with new and old drugs : Synthetic amphetamines, cathinones, cannabinoids and opioids-an overview].
    Strube J; Schaper A
    Med Klin Intensivmed Notfmed; 2019 Nov; 114(8):684-692. PubMed ID: 29404633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.
    Martinotti G; Santacroce R; Papanti D; Elgharably Y; Prilutskaya M; Corazza O
    CNS Neurol Disord Drug Targets; 2017; 16(5):567-575. PubMed ID: 28412921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues.
    Schep LJ; Slaughter RJ; Hudson S; Place R; Watts M
    Hum Exp Toxicol; 2015 May; 34(5):557-60. PubMed ID: 25233895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids.
    Glue P; Courts J; MacDonald M; Gale C; Mason E
    N Z Med J; 2015 May; 128(1414):15-8. PubMed ID: 26117386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques.
    Hutter M; Broecker S; Kneisel S; Auwärter V
    J Mass Spectrom; 2012 Jan; 47(1):54-65. PubMed ID: 22282090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
    Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
    Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
    Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
    Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
    Dresen S; Ferreirós N; Pütz M; Westphal F; Zimmermann R; Auwärter V
    J Mass Spectrom; 2010 Oct; 45(10):1186-94. PubMed ID: 20857386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect and occurrence of synthetic cannabinoids].
    Tuv SS; Strand MC; Karinen R; Øiestad EL; Christophersen AS; Vindenes V
    Tidsskr Nor Laegeforen; 2012 Oct; 132(20):2285-8. PubMed ID: 23736196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.